ATXI

About ATXI

Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company seeks to develop and commercialize its product principally for use in the acute/intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, for the treatment of post-operative acute pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works through the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. These opioid and non-opioid modes of action are synergistic, providing multimodal therapy with the use of a single drug. Tramadol is marketed as an oral agent indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Ultracet, a combination product containing tramadol and acetaminophen, is also marketed in the United States (Ortho-McNeil-Janssen).